Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Intractable focal onset seizures Clinical criteria: Treatment Phase: Continuing treatment Patient must have previously been treated with PBS-subsidised treatment with this drug for this condition, AND The treatment must not be given concomitantly with levetiracetam.
“Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain. Binding to SV2A is considered to be the primary mechanism for brivaracetam anticonvulsant activity, however, the precise mechanism by which brivaracetam exerts is anticonvulsant activity has not been fully elucidated.”
“The terminal plasma half-life (t 1/2 ) is approximately 9 hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro, the hydroxylation of brivaracetam is mediated primarily by CYP2C19. In vivo, in human subjects possessing ineffective mutations of CYP2C19, production of the hydroxy metabolite is decreased 10-fold while brivaracetam itself is increased by 22% or 42% in individuals with one or both mutated alleles. Therefore, inhibitors of CYP2C19 are unlikely to have a significant effect on brivaracetam.”